ABSTRACT
Objective:To analyze the correlation between ambulatory blood pressure variability and the progression of subjective cognitive decline (SCD).Methods:In this prospective observational study, the overall sampling method was used to continuously select 100 patients with SCD in the Department of Neurology, Changshu First People′s Hospital and Changshu Xinzhuang People′s Hospital from January 1 2016 to June 30 2017. The baseline demographic characteristics of the patients were collected. The Chinese version of SCD-Q9 questionnaire was used to self-evaluate SCD, and the Montreal Cognitive Assessment Scale (MoCA) was used to evaluate objective cognitive impairment. All patients received 24 h ambulatory blood pressure monitoring, and 24 h systolic coefficient of variation (SCV) and diastolic coefficient of variation (DCV) were calculated. The follow-up period was 4 years after the first visit, and the MoCA scale was evaluated once a year. Finally, 83 patients completed the follow-up and were included in this study. According to the MoCA score at the end of follow-up (<26 or ≥26), the patients were divided into progression group (39 cases) and non-progression group (44 cases). The difference of MoCA score between baseline and last follow-up was calculated in the progression group. The difference in demographic characteristics between the two groups was compared with χ2 test. The difference of 24 h SCV and 24 h DCV between the two groups were compared by rank sum test. The correlation between 24 h SCV and MoCA score difference or SCD-Q9 score in the progression group were tested by multiple linear regression analysis. Results:The 4-year progression rate of SCD patients was 46.99% (39/83). There was no significant differences in baseline age, gender, education level, medical history, smoking history, SCD-Q9 score and MoCA score between the progressive group and the non-progressive group (all P>0.05). The 24 h SCV in the progressive group was significantly higher than that in the non-progressive group [13.4% (9.9%, 15.6%) vs 10.9% (9.7%, 12.7%), U=594.50, P=0.016]. There was no significant difference in 24 h DCV between the two groups ( P>0.05). In progressive group, the 24 h SCV was negatively correlated with MoCA score difference ( r=-0.368, P=0.021). Conclusion:There is a correlation between ambulatory blood pressure variability and SCD progression, high 24 h SCV may be one of the factors of SCD progression and has certain predictive value.
ABSTRACT
As a preclinical stage of Alzheimer′s disease, subjective cognitive decline has attracted extensive attention of researchers at home and abroad in recent years. At this stage, targeted intervention according to the influencing factors of subjective cognitive decline is an effective entry point to delay the occurrence of dementia. This paper summarized the evaluation method, influencing factors and preventive measures of subjective cognitive decline, in order to provide a theoretical basis for the prevention and treatment of cognitive decline in the elderly.
ABSTRACT
Objective:To develop a Beijing norm of Memory and Executive Screening (MES) scale to facilitate its further promotion and application in the future.Methods:Study subjects were selected based on the inclusion and exclusion criteria, including patients who visited the memory clinic of Xuanwu Hospital of Capital Medical University from March 20, 2017 to January 6, 2021, and normal people recruited simultaneously from community, and trained and qualified investigators conducted questionnaire surveys through face-to-face interviews. Then strict quality control, data collection and statistical analysis were performed.Results:A total of 607 participants were included, including 239 normal people, 293 individuals with subjective cognitive decline (SCD), and 75 individuals with mild cognitive impairment (MCI). There was a negative correlation between the scores of MES and age ( r=-0.19, P<0.001), but a positive correlation between scores of MES and education level ( r=0.29, P<0.001). The optimal cut-off value of this scale in Beijing was 86 points, the area under curve (AUC) of the cut-off value to distinguish MCI was 0.847 (normal people vs MCI) and 0.826 (SCD vs MCI), and after adding demographic variables, AUC showed slight increase (0.847 to 0.850 and 0.826 to 0.847), whereas the differences were not statistically significant ( Znormal peoplevsMCI=0.49, ZSCDvsMCI=1.21, P>0.05). And there was no statistically significant difference between MES and Montreal Cognitive Assessment scales in diagnostic power for normal people and people with MCI ( Zscale alone=1.03, Zafter adding demographic variables=1.13, P>0.05). Conclusions:The MES scale has a better distinguishing power for MCI, and its optimal cut-off value in Beijing is 86 points, which is different from previous studies. In the future, the sample size needs to be further expanded to verify this norm.
ABSTRACT
Objective:To investigate the characteristics and clinical related factors of Parkinson′s disease (PD) patients with subjective cognitive decline (SCD).Methods:Ninety-nine PD patients with normal cognitive function enrolled in Beijing Hospital from January to December 2018 were collected for the study. Patients with PD were divided into groups with ( n=57) and without ( n=42) SCD using the first question in Part 1 of the Unified Parkinson′s Disease Rating Scale (UPDRS). All patients were assessed by Montreal Cognitive Assessment (MoCA), modified Hoehn-Yahr grading, UPDRS, Hamilton Rating Scale for Depression (HAMD), Hamilton Rating Scale for Anxiety (HAMA), Parkinson′s Disease Sleep Scale, Ability of Daily Living Scale and 39-item Parkinson′s Disease Questionnaire (PDQ-39). Levodopa equivalent dose conversion was performed for patients taking anti-PD drugs. Patients′ self-reported years of formal education were collected. Results:The proportion of PD with SCD in this group was 57.58% (57/99). There were statistically significant differences in MoCA [28.00 (27.00, 29.00) vs 28.00 (27.00, 29.00) ,Z=-2.28, P=0.023], HAMD [6.00 (5.00, 8.50) vs 5.00 (2.00, 8.00), Z=-2.23, P=0.026], HAMA [7.00 (6.00, 11.00) vs 6.00 (3.00, 8.25) , Z=-2.70, P=0.007], PDQ-39-emotional health [2.00 (0, 5.00) vs 1.00 (0, 3.00), Z=-2.03, P=0.042] and PDQ-39-cognitive scores [4.00 (2.00, 5.00) vs 2.00 (0, 4.00), Z=-3.42, P=0.001] between PD with and without SCD groups. SCD was correlated with MoCA ( r=-0.23, P=0.022), HAMD ( r=0.23, P=0.025) and HAMA ( r=0.27, P=0.006) scores to varying degrees. When controlling for HAMD and HAMA scores, the correlation between SCD and MoCA scores ( r′=-0.18, P=0.084) was no longer existed. Conclusions:SCD is common in PD patients with normal cognitive function and is associated with poorer cognitive performance and more severe symptoms of depression and anxiety. In this group of patients, the relationship between SCD and affective symptoms may be greater than that of objective overall cognitive function, which is worthy of further studies.
ABSTRACT
ABSTRACT. The preclinical stages of dementia include subtle neurocognitive changes that are not easily detected in standard clinical evaluations. Neuropsychological evaluation is important for the classification and prediction of deterioration in all the phases of dementia. Objective: Compare the neuropsychological performance in healthy older adults with subjective cognitive decline (SCD) and with mild cognitive impairment (MCI) using principal components analysis. Methods: We evaluated 94 older adults with a clinical protocol which included general measures of mental, emotional and functional state. The neuropsychological protocol included tasks of memory, executive function, attention, verbal fluency and visuoconstructional abilities. We used principal component analysis (PCA) to reduce variables´ dimensionality on neuropsychological evaluation. Results: 33(35%) participants had a normal cognitive function, 35(37%) had subjective cognitive decline and 26(28%) had a mild cognitive impairment. The PCA showed seven factors: processing speed, memory, visuoconstruction, verbal fluency and executive components of cognitive flexibility, inhibitory control and working memory. ANOVA had shown significant differences between the groups in the memory (F=4.383, p=0.016, η2p=0.087) and visuoconstructional components (F=5.395, p=0.006, η2p=0.105). Post hoc analysis revealed lower memory scores in MCI than SCD participants and in visuospatial abilities between MCI and SCD and MCI and Normal participants. Conclusions: We observed differentiated cognitive profiles among the participants in memory and visuoconstruction components. The use of PCA in the neuropsychological evaluation could help to make a differentiation of cognitive abilities in preclinical stages of dementia.
RESUMO. Os estágios pré-clínicos da demência incluem mudanças neurocognitivas sutis que não são facilmente detectadas nas avaliações clínicas padrão. A avaliação neuropsicológica é importante para a classificação e predição da deterioração em todas as fases da demência. Objetivo: Comparar o desempenho neuropsicológico em idosos saudáveis com declínio cognitivo subjetivo (DCS) e com comprometimento cognitivo leve (CCL) por meio da análise de componentes principais. Métodos: Avaliaram-se 94 idosos com um protocolo clínico que incluía medidas gerais do estado mental, emocional e funcional. O protocolo neuropsicológico incluiu tarefas de memória, função executiva, atenção, fluência verbal e habilidades visuoconstrutivas. Utilizou-se a análise de componentes principais (PCA, na sigla em inglês) para reduzir a dimensionalidade das variáveis na avaliação neuropsicológica. Resultados: Um total de 33 (35%) participantes apresentavam função cognitiva normal, 35 (37%) declínio cognitivo subjetivo e 26 (28%) comprometimento cognitivo leve. A PCA apresentou sete fatores: velocidade de processamento, memória, visuoconstrução, fluência verbal e componentes executivos de flexibilidade cognitiva, controle inibitório e memória de trabalho. ANOVA mostrou diferenças significativas entre os grupos na memória (F=4,383, p=0,016, η2p=0,087) e componentes visuoconstrutivos (F=5,395, p=0,006, η2p=0,105). A análise post hoc revelou escores de memória mais baixos no CCL do que os participantes com DCS e nas habilidades visuoespaciais entre CCL e DCS e CCL e participantes normais. Conclusões: Observaram-se perfis cognitivos diferenciados entre os participantes nos componentes de memória e visuoconstrução. O uso da PCA na avaliação neuropsicológica poderia auxiliar na diferenciação das habilidades cognitivas em estágios pré-clínicos da demência.
Subject(s)
Cognitive Dysfunction , NeuropsychologyABSTRACT
Objective@#To investigate the neurocognitive characteristics and related factors in the elderly with subjective cognitive decline.@*Methods@#Among the 1 850 elderly volunteers aged over 50, 377 cognitive normal elderly (NC group), 234 subjective cognitive decline (SCD Group) and 291 patients with mild cognitive impairment (aMCI Group) were screened with the brief elderly cognitive screening questionnaire and the elderly rapid cognitive screening scale.They were all received clinical interview and examination and core neurocognitive test.@*Results@#(1) There were statistically significant differences in the three groups on the age, education, occupation, HAMD, low density lipoprotein and blood pressure (P<0.01). (2) The score of the picture-symbol association in SCD group(8.94±4.05)was lower than that in NC group(9.83±4.18)and higher than that in aMCI group (7.12±4.17)(all P<0.05), while the scores of the other neuropsychological tests were higher than those in aMCI group.There were no statistically significant difference between SCD group and NC group on the other neuropsychological tests(P>0.05). (3)The SCD was mainly influenced by age(β=0.063, OR=1.065, 95%CI=1.033-1.099), depression(β=0.182, OR=1.199, 95%CI=1.084-1.327)and hypertension(β=0.473, OR=1.604, 95%CI=1.185-2.171)(all P<0.01). And the aMCI was mainly influenced by age(β=0.078, OR=1.081, 95%CI=1.048-1.115), education(β=-0.174, OR=0.840, 95%CI=0.778-0.907), occupation(β=-0.406, OR=0.666, 95%CI=0.535-0.830)and low density lipoprotein(β=-0.451, OR=0.637, 95%CI=0.497-0.816)(all P<0.01 ).@*Conclusion@#Objective neurocognitive function of the elderly with subjective cognitive decline is basically normal.Age, depression and hypertension are risk factors of subjective cognitive decline.
ABSTRACT
Objective To investigate the neurocognitive characteristics and related factors in the elderly with subjective cognitive decline. Methods Among the 1 850 elderly volunteers aged over 50,377 cognitive normal elderly (NC group),234 subjective cognitive decline ( SCD Group) and 291 patients with mild cognitive impairment (aMCI Group) were screened with the brief elderly cognitive screening question-naire and the elderly rapid cognitive screening scale. They were all received clinical interview and examina-tion and core neurocognitive test. Results ( 1) There were statistically significant differences in the three groups on the age,education,occupation,HAMD,low density lipoprotein and blood pressure (P<0. 01). (2) The score of the picture-symbol association in SCD group( 8. 94 ± 4. 05) was lower than that in NC group (9. 83±4. 18)and higher than that in aMCI group (7. 12±4. 17)(all P<0. 05),while the scores of the other neuropsychological tests were higher than those in aMCI group. There were no statistically significant differ-ence between SCD group and NC group on the other neuropsychological tests(P>0. 05). (3) The SCD was mainly influenced by age( β=0. 063, OR=1. 065,95% CI=1. 033-1. 099), depression ( β=0. 182,OR=1. 199,95%CI=1. 084-1. 327) and hypertension(β=0. 473,OR=1. 604,95% CI=1. 185-2. 171) ( all P<0. 01). And the aMCI was mainly influenced by age(β=0. 078,OR=1. 081,95%CI=1. 048-1. 115),educa-tion(β=-0. 174,OR=0. 840,95%CI=0. 778-0. 907),occupation( β=-0. 406,OR=0. 666,95%CI=0. 535-0. 830)and low density lipoprotein(β=-0. 451,OR=0. 637,95%CI=0. 497-0. 816)(all P<0. 01 ). Conclu-sion Objective neurocognitive function of the elderly with subjective cognitive decline is basically normal. Age,depression and hypertension are risk factors of subjective cognitive decline.
ABSTRACT
Objective Using olfactory task functional magnetic resonance imaging (fMRI) to investigate the difference in brain olfactory activation between patients with subjective cognitive decline and normal elderly subjects, and to explore the objective image markers for early identification and evaluation the progression from SCD to Alzheimer′s disease (AD). Methods Twenty patients with SCD (SCD group) and twenty matched normal elderly subjects (NC group) were recruited from the community from March 2017 to December 2018. A full neuropsychological scale tests battery, olfactory behavioral tests and olfactory task?fMRI were performed. The differences between olfactory behavior, neuropsychological scales, and task?fMRI brain activation between the two groups were tested. Further, brain regions, which had significantly different activations under task?fMRI, were used as seeds for resting state functional connectivity (FC) analysis. Finally, the correlations between brain activation and olfactory behavior along with clinical neuropsychological scale tests were examined. Results The results of this study showed SCD had a significant decrease in olfactory behavior (olfactory recognition ability) compared with NC (t=-3.042, P<0.01), and there was no statistically significant difference in olfactory threshold. Significant declines were also observed in the SCD self?rating scale (t=6.973, P<0.01), the immediate (t=-4.623, P<0.01) and delayed (t=-2.746, P<0.01) testing of Philadelphia word learning, while the remaining neuropsychological scales were normal. In the olfactory task?fMRI, activation of bilateral primary olfactory cortical regions was significantly reduced in SCD patients, including bilateral entorhinal cortex, amygdala, piriform cortex, anterior olfactory nucleus, and head of the hippocampus. The resting state functional connectivity with the primary olfactory cortex (POC) as the seed showed that the functional connectivity between the olfactory system and the default model network (DMN) of SCD patients was significantly weakened (AlphaSim correction with voxel level P<0.01 and cluster level P<0.05). The Beta value of the left POC was significantly positively correlated with the olfactory threshold and Montreal cognitive assessment (MoCA) (r=0.329, P=0.041; r=0.317, P=0.046). Partial correlation analysis indicated that there was a significantly positive correlation between the FC of the left POC with the right/left inferior frontal gyrus, the left frontal middle gyrus and the right inferior parietal, and the score of immediate Philadelphia word learning test(r=0.411, P=0.008; r=0.400, P=0.011; r=0.329, P=0.003; r=0.454, P=0.003). The FC between the left POC and the right inferior temporal gyrus was negatively correlated with the score of trail making test (TMT) B, and the FC between the left POC and the right inferior was negatively correlated with score of language fluency test (r=-0.317, P=0.047; r=-0.333, P=0.036). The FC between the right POC and the left inferior parietal was positively correlated with the score of immediate Philadelphia word learning (r=0.315, P=0.048), while the FC between right POC and left middle occipital gyrus was negatively corrected with Language Fluency Test (r=-0.403, P=0.01). Conclusion Olfactory function has been impaired in SCD patients with normal standard cognition and phychiatric rating scales, and the changes in the activation of the primary olfactory cortex, such as the entorhinal cortex, may be an early neural circuit damage biomarker for objective evaluation of SCD.
ABSTRACT
BACKGROUND AND PURPOSE: Subjective cognitive decline (SCD) may be the first symptomatic stage of Alzheimer's disease (AD). Hence, a screening tool to characterize the patients' complaints and assess the risk of AD is required. We investigated the SCD neuroimaging biomarker distributions and the relevance between the self-report questionnaire and Alzheimer's pathologic changes. METHODS: Individuals aged 50 and above with consistent cognitive complaints without any objective cognitive impairments were eligible for the study. The newly developed questionnaire consisted of 2 parts; 10 questions translated from the ‘SCD-plus criteria’ and a Korean version of the cognitive failure questionnaire by Broadbent. All the subjects underwent physical examinations such as blood work, detailed neuropsychological tests, the self-report questionnaire, brain magnetic resonance imagings, and florbetaben positron emission tomography (PET) scans. Amyloid PET findings were interpreted using both visual rating and quantitative analysis. Group comparisons and association analysis were performed using SPSS (version 18.0). RESULTS: A total of 31 participants with SCD completed the study and 25.8% showed positive amyloid depositions. The degree of periventricular white matter hyperintensities (WMH) and hippocampal atrophy were more severe in amyloid-positive SCDs compared to the amyloid-negative group. In the self-reported questionnaire, the ‘informant's report a decline’ and ‘symptom's onset after 65 years of age’ were associated with more Alzheimer's pathologic changes. CONCLUSIONS: Amyloid-positive SCDs differed from amyloid-negative SCDs on WMH, hippocampal atrophy, and a few self-reported clinical features, which gave clues on the prediction of AD pathology.
Subject(s)
Alzheimer Disease , Amyloid , Atrophy , Biomarkers , Brain , Cognition Disorders , Mass Screening , Neuroimaging , Neuropsychological Tests , Pathology , Physical Examination , Plaque, Amyloid , Positron-Emission Tomography , White MatterABSTRACT
Subjective cognitive decline (SCD) represents subjective complaints about cognitive decline in the absence of objective impairment in neuropsychological tests. Recently, growing evidence has suggested that SCD might be the first symptomatic stage of Alzheimer's disease (AD) spectrum disorders. However, SCD is a heterogeneous condition mixed with AD and non-AD related conditions. Hence, refinement of evidence from previous reports and standardization of the concept about SCD are needed to define appropriate target population with AD pathology. In this article, we review previous studies involving subjects with SCD, the new proposed research criteria, and characteristics of SCD in the aspect of preclinical AD. Biomarker status of SCD is also addressed. Future researches on SCD require a longitudinal follow-up with sufficient biomarker studies and proper outcome measures.
Subject(s)
Alzheimer Disease , Follow-Up Studies , Health Services Needs and Demand , Neuropsychological Tests , Outcome Assessment, Health Care , PathologyABSTRACT
ABSTRACT Background: Mild cognitive impairment is considered as the first clinical manifestation of Alzheimer's disease (AD), when the individual exhibits below performance on standardized neuropsychological tests. However, some subjects before having a lower performance on cognitive assessments already have a subjective memory complaint. Objective: A review about subjective cognitive decline, the association with AD biomarkers and risk of conversion to dementia. Methods: We performed a comprehensive non-systematic review on PubMed. The keywords used in the search were terms related to subjective cognitive decline. Results: Subjective cognitive decline is characterized by self-experience of deterioration in cognitive performance not detected objectively through formal neuropsychological testing. However, various terms and definitions have been used in the literature and the lack of a widely accepted concept hampers comparison of studies. Epidemiological data have shown that individuals with subjective cognitive decline are at increased risk of progression to AD dementia. In addition, there is evidence that this group has a higher prevalence of positive biomarkers for amyloidosis and neurodegeneration. However, Alzheimer's disease is not the only cause of subjective cognitive decline and various other conditions can be associated with subjective memory complaints, such as psychiatric disorders or normal aging. The features suggestive of a neurodegenerative disorder are: onset of decline within the last five years, age at onset above 60 years, associated concerns about decline and confirmation by an informant. Conclusion: These findings support the idea that subjective cognitive complaints may be an early clinical marker that precedes mild cognitive impairment due to Alzheimer's disease.
RESUMO Introdução: O comprometimento cognitivo leve é considerado como a primeira manifestação clínica da doença de Alzheimer, quando o indivíduo exibe um desempenho abaixo para idade e escolaridade em testes neuropsicológicos padronizados. No entanto, alguns já apresentam uma queixa subjetiva de memória antes doprejuízo nas avaliações cognitivas. Objetivo: Fazer uma revisão sobre o declínio cognitivo subjetivo, a associação com biomarcadores da doença de Alzheimer e o risco de conversão para demência. Métodos: Realizou-se uma revisão não-sistemática no PubMed. As palavras-chave utilizadas na busca foram relacionadas ao declínio cognitivo subjetivo. Resultados: O declínio cognitivo subjetivo é caracterizada por uma autoexperiência da deterioração no desempenho cognitivo não detectado objetivamente por meio de testes neuropsicológicos formais. Todavia, vários termos e definições são utilizados na literatura e a falta de um conceito largamente aceito dificulta uma comparação. Os dados epidemiológicos mostram que indivíduos com declínio cognitivo subjetivo estão em maior risco de progressão para demência. Além disso, há evidências de que este grupo tem maior prevalência de biomarcadores positivos para amiloidose e neurodegeneração. Porém, a doença de Alzheimer não é a única causa e várias outras condições podem estar associadas, tais como distúrbios psiquiátricos ou o envelhecimento normal. As características sugestivas de uma doença neurodegenerativa são: início nos últimos cinco anos, início acima de 60 anos, estar preocupado com declínio e confirmação por um informante. Conclusão: Estes resultados suportam a ideia de que o declínio cognitivo subjetivo pode ser um marcador clínico precoce que precede comprometimento cognitivo leve devido à doença de Alzheimer.
Subject(s)
Humans , Biomarkers , Cognition Disorders , Alzheimer DiseaseABSTRACT
BACKGROUND AND PURPOSE: Subjective cognitive decline has been proposed as a potential indicator of the preclinical state of Alzheimer's disease (AD). The results of the studies of cortical atrophy on brain MRIs in subjects with subjective cognitive decline are inconsistent across the literatures. We investigated whether subjects with subjective cognitive decline had less gray matter volume compared to controls without subjective cognitive decline as per brain MRI. METHODS: Thirty-six subjects with subjective cognitive decline and thirty-three controls without subjective cognitive decline were recruited retrospectively from among the patients who had visited the department of neurology at Inha University Hospital between January 2008 and December 2010. All subjects had undergone a brain MRI scan including 3D T1-weighted spoiled gradient recalled echo imaging. We used voxel-based morphometry (VBM) to examine gray matter volumes between the two groups, after controlling for age, sex, education, and total intracranial volumes (TIV). RESULTS: There were no significant differences in age, gender, education, and TIV between the two groups. In comparison to controls without subjective cognitive decline, subjects with subjective cognitive decline showed gray matter atrophy in the left superior and medial frontal gyri, left superior and inferior parietal lobules, and right precuneus and insular in the VBM analysis. CONCLUSIONS: Individuals with subjective cognitive decline encountered in clinical settings have greater similarity to an AD gray matter atrophy pattern compared with cognitively normal individuals without subjective cognitive decline.
Subject(s)
Humans , Alzheimer Disease , Atrophy , Brain , Education , Magnetic Resonance Imaging , Neurology , Rabeprazole , Retrospective StudiesABSTRACT
Along with the development of biomarkers, the diagnostic criterion for early AD is continuously progressing until the preclinical stage of AD, on the base of which, the conception of subjective cognitive decline was raised.In order to highlight new ideas of the early diagnosis for AD in its preclinical stage, the current paper will talk about SCD in connection with neuroimaging tech-niques and examination of cerebrospinal fluid.
ABSTRACT
Alzheimer′s disease ( AD) is the most common disease leading to dementia .With aging of the population , the morbidity of AD is increasing significantly , which brings serious burden personally and socially .So the early diagnosis of AD has be-come the hotspot in the current research field .In order to highlight new ideas for the early diagnosis of AD , the current review will ana-lyze from the first international diagnostic criteria for AD dementia to the latest conceptual framework for research on subjective cogni -tive decline in preclinical Alzheimer′s disease.